These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33515341)

  • 1. Co-delivery of miRNA-15a and miRNA-16-1 using cationic PEGylated niosomes downregulates Bcl-2 and induces apoptosis in prostate cancer cells.
    Ghaffari M; Kalantar SM; Hemati M; Dehghani Firoozabadi A; Asri A; Shams A; Jafari Ghalekohneh S; Haghiralsadat F
    Biotechnol Lett; 2021 May; 43(5):981-994. PubMed ID: 33515341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy.
    Hemati M; Haghiralsadat F; Yazdian F; Jafari F; Moradi A; Malekpour-Dehkordi Z
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1295-1311. PubMed ID: 30033768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient Delivery of Gold Nanoparticles and miRNA-33a Via Cationic PEGylated Niosomal Formulation to MCF-7 Breast Cancer Cells.
    Ahmadi SM; Seyedabadi M; Ebrahimnejad P; Abasi M; Nokhodchi A
    AAPS PharmSciTech; 2024 Sep; 25(7):213. PubMed ID: 39266895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.
    Zare-Zardini H; Alemi A; Taheri-Kafrani A; Hosseini SA; Soltaninejad H; Hamidieh AA; Haghi Karamallah M; Farrokhifar M; Farrokhifar M
    Drug Des Devel Ther; 2020; 14():3315-3324. PubMed ID: 32884236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-143 Induces the Apoptosis of Prostate Cancer LNCap Cells by Suppressing Bcl-2 Expression.
    Ma Z; Luo Y; Qiu M
    Med Sci Monit; 2017 Jan; 23():359-365. PubMed ID: 28109198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miRNA-29b Inhibits Prostate Tumor Growth and Induces Apoptosis by Increasing Bim Expression.
    Sur S; Steele R; Shi X; Ray RB
    Cells; 2019 Nov; 8(11):. PubMed ID: 31752117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
    Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
    Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor suppressor miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate cancer cells.
    Lin YC; Lin JF; Tsai TF; Chou KY; Chen HE; Hwang TI
    Asian J Surg; 2017 Sep; 40(5):396-406. PubMed ID: 27519795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.
    Alemi A; Zavar Reza J; Haghiralsadat F; Zarei Jaliani H; Haghi Karamallah M; Hosseini SA; Haghi Karamallah S
    J Nanobiotechnology; 2018 Mar; 16(1):28. PubMed ID: 29571289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LINC00473 promotes the Taxol resistance via miR-15a in colorectal cancer.
    Wang L; Zhang X; Sheng L; Qiu C; Luo R
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30126852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [miR-15a and miR-16 modulate drug resistance by targeting bcl-2 in human colon cancer cells].
    Xu M; Zhou B; Wang G; Wang G; Weng X; Cai J; Li P; Chen H; Jiang X; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):897-902. PubMed ID: 25623762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale screening identifies a novel microRNA, miR-15a-3p, which induces apoptosis in human cancer cell lines.
    Druz A; Chen YC; Guha R; Betenbaugh M; Martin SE; Shiloach J
    RNA Biol; 2013 Feb; 10(2):287-300. PubMed ID: 23353574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors.
    Diniz MG; Gomes CC; de Castro WH; Guimarães AL; De Paula AM; Amm H; Ren C; MacDougall M; Gomez RS
    Cell Oncol (Dordr); 2012 Aug; 35(4):285-91. PubMed ID: 22684875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.
    Chen CQ; Chen CS; Chen JJ; Zhou LP; Xu HL; Jin WW; Wu JB; Gao SM
    Mol Cell Biochem; 2013 Nov; 383(1-2):137-48. PubMed ID: 23867991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of miR-423-5p suppressed prostate cancer through targeting GRIM-19.
    Lin H; Lin T; Lin J; Yang M; Shen Z; Liu H; Zou Z; Zheng Z
    Gene; 2019 Mar; 688():93-97. PubMed ID: 30415005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of miR-15a on induction of apoptosis in breast cancer MCF-7 cells].
    Liu YH; Hong LQ; Yu WQ; Li XY; Zheng XY
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):827-30. PubMed ID: 22335947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EpCAM Aptamer-Functionalized Cationic Liposome-Based Nanoparticles Loaded with miR-139-5p for Targeted Therapy in Colorectal Cancer.
    Zhao Y; Xu J; Le VM; Gong Q; Li S; Gao F; Ni L; Liu J; Liang X
    Mol Pharm; 2019 Nov; 16(11):4696-4710. PubMed ID: 31589818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated synthetic surfactant vesicles (Niosomes): novel carriers for oligonucleotides.
    Huang Y; Chen J; Chen X; Gao J; Liang W
    J Mater Sci Mater Med; 2008 Feb; 19(2):607-14. PubMed ID: 17619962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abberent expression of oncogenic and tumor-suppressive microRNAs and their target genes in human adenocarcinoma alveolar basal epithelial cells.
    Tafsiri E; Darbouy M; Shadmehr MB; Cho WC; Karimipoor M
    J Cancer Res Ther; 2016; 12(1):395-400. PubMed ID: 27072269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.